While sensitive to internal carotid artery (ICA) occlusion, carotid ultrasound can produce false-positive results. CT angiography (CTA) has a high specificity for ICA occlusion and is safer and cheaper than catheter angiography, although less accurate. We determined the cost-effectiveness of CTA versus catheter angiography for confirming an ICA occlusion first suggested by carotid ultrasound.
Introduction
Carotid endarterectomy (CEA) is superior to medical therapy in prevention of stroke in patients with symptomatic severe carotid artery disease. 1, 2 Initial screening for carotid disease in stroke patients is commonly performed with carotid ultrasound (CUS). 3 In 15% of symptomatic patients, CUS suggests an internal carotid artery (ICA) occlusion. However, because of technical limitations of CUS, the artery is actually patent in up to 14% of these cases. 4 Therefore, when a CUS suggests an ICA occlusion, further testing is often deemed necessary.
The second test selected for confirmation of a suspected occlusion is often intra-arterial conventional angiography (CA) or CT angiography (CTA). These two tests, CA and CTA are not as flow-dependent as CUS and MR angiography (MRA), [5] [6] [7] and therefore are more accurate in differentiating between a complete occlusion and severe stenosis. 8, 9 CA is considered the reference standard for assessing the degree of ICA stenosis. CA carries with it a risk of stroke and is expensive, while CTA is safer and less costly than CA, but is less accurate. We therefore performed a cost-utility analysis to determine the costeffectiveness of using CTA compared with CA to confirm a suspected ICA occlusion.
Methods Model
A decision analytic model was constructed to consider the use of two alternative strategies, CTA and CA, to confirm the diagnosis of an ICA occlusion suspected based on CUS in a hypothetical cohort of symptomatic patients. Four possible outcomes were considered: death from the diagnostic test, stroke from the diagnostic test, stroke by 2 years, and death by 2 years. Two-years was selected for the time-horizon as the risk of stroke for those with a severe stenosis who undergo CEA approximates those treated medically after 2-3 years. 10 Furthermore, estimates of probabilities beyond 2 years are less well-established. Long-term outcomes were modeled using Markov models. Markov processes use simulation techniques to evaluate a hypothetical cohort of patients' prognoses given repeated exposure to a particular health risk. Each hypothetical patient who did not have a diagnostic test-related stroke was modeled to start in the well state. He/she could transition from well to stroke, or dead as dictated by monthly Markov transition probabilities. A diagram of the Markov model in isolation is shown in Figure 1 . Model inputs were derived from the literature. All estimates derived from the literature were ex- Probability of ICA occlusion .89 (33) .86 (4) .97 (11) CTA sensitivity .97 (13) .92 (13) 1.0 (13) CTA specificity .99 (13) .98 (13) 1.0 (13) Stroke CTA 0 --CA sensitivity and specificity 1.0 --Death CTA .000006 (16) .000004 (35) .0005 Stroke CA .01 (15) .0014 (36) .015 Death CA .0006 (15, 36) .0002 .0010 Monthly probability of death after ICA occlusion .0056 (14) .004 .007 Monthly probability of death 70-99% stenosis .0048 (1) .003 .006 Monthly probability of stroke after ICA occlusion .0048 (14) .003 .006 Monthly probability of stroke after ICA occlusion with CEA .0053 (14) . plored in a one-way sensitivity analysis across a plausible range of values, as shown in Table 1 . Two-way sensitivity analyses were also conducted with both CTA sensitivity and specificity and several key variables: probability of ICA occlusion at the time of the test, probability of stroke from CA, and the utility of stroke. A "worst-case" scenario analysis was then performed biasing the analysis against CTA. This used the costs, sensitivities, specificities, and complications found in Table 1 , which were favoring CA and disadvantaging CTA: the lowest values for CTA sensitivity and specificity were used, while the highest costs and complications for CTA and the lowest values for complications and costs for CA were used. We further explored the effect of biasing variables on the model results by only partially biasing the analysis against CTA. First all CTA variables that disadvantaged CTA were used. Separately we used all CA variables that favored CA. As contrast-enhanced MRA is often used as a screening test for ICA disease, the analysis was repeated substituting the accuracy of contrast-enhanced MRA for that of CUS. The decision tree was analyzed using Data 4.0 (TreeAge software, Inc, Williamstown, MA).
Baseline Probability of ICA Occlusion
The positive predictive value of carotid ultrasound in detecting a complete ICA occlusion was estimated to be .97. 11 This value was used for the true baseline estimate of ICA occlusion in those undergoing CA or CTA. The analysis was repeated assuming contrast-enhanced MRA was used to screen individuals for carotid disease using a baseline prevalence equal to the positive predictive value of contrast-enhanced MRA for ICA occlusion, .93. 12 The value of the probability of occlusion was allowed to vary in sensitivity analyses (see Table 1 ). It was assumed that a 0-69% stenosis and complete occlusion are never mistaken for one another by any of the diagnostic tests.
Accuracy of CTA
Koelemay et al. 13 systematically reviewed the literature analyzing the aggregated sensitivity and specificity of CTA. Sensitivity and specificity values were obtained from this study and were allowed to vary in sensitivity analysis through the range of their 99% confidence intervals.
Risks
Estimates of stroke and mortality probabilities can be found in Table 1 . Monthly probabilities of stroke were estimated from the North American Symptomatic Carotid Endarterectomy Trial (NASCET) 1 for patients with 70-99% stenoses (incorporating strokes and deaths as a result of CEA where applicable), and from an analysis of prospective and retrospective series for those with complete occlusions.
14 Two-year mortality for CEA and non-CEA groups was not significantly different in the NASCET study and thus were averaged together. It was assumed that there was no benefit conferred by CEA in patients with complete occlusions and that this surgery would yield a 1% higher stroke risk above baseline when performed in those with a complete occlusion.
For the reference case analysis, a 1% stroke risk and a .06% death risk associated with CA were estimated from data pooled from eight prospective studies. 15 It was assumed based on the literature that the only significant complication from CTA was death related to contrast administration. This was estimated to occur in .0006% of contrast injections. 16 
Outcomes
Utilities are measures between 0, representing death, and 1, representing perfect health, which can be assigned to a health state in order to account for the relative adverse effect the condition has on quality of life. Quality-adjusted life years (QALYs) were calculated by multiplying utilities by life-years spent in that health state. Utility measures were estimated from the literature. The utility value used for stroke, .6, was obtained from healthy subjects using the standard gamble approach, 17 but this value was allowed to vary widely in sensitivity analyses. 17 
Costs
A societal perspective, which considers costs regardless of the identity of the payer, was taken. All costs were converted to 2004 US dollars and are found in Table 1 . The cost of CA and CTA were estimated from Medicare fee schedules and included technical and physician components. The cost of CEA, monthly cost of stroke, and cost of death from stroke were estimated from studies where Medicare reimbursement was used. [18] [19] [20] Costs, calculated using the cost-to-charge ratio or Medicare allowable payments, included hospitalization, physician time, rehabilitation, durable medical equipment, and skilled nursing home care. 20 Nonskilled nursing home care and outpatient medications were also considered.
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Results
The average patient undergoing CTA experienced 1.83 QALYs at a cost of $9,178; while those undergoing CA experienced 1.82 QALYs at a cost of $11,531, resulting in an incremental cost of $2,353 for CA. The cost-effectiveness of CTA was $5,012 and for CA was $6,322. Repeating the analysis assuming that contrast-enhanced MRA was used for screening yielded similar results: CTA remained dominant over CA. Each variable was allowed to vary in one-way sensitivity analysis using the value ranges found in Table 1 . The results of the analysis were insensitive to these alterations, with the CTA strategy remaining dominant over CA. Two-way sensitivity analyses performed with CTA sensitivity and specificity and the key variables (probability of ICA occlusion at the time of the test, probability of stroke from CA, and the utility of stroke) also supported CTA as the preferred strategy throughout the ranges tested.
In the "worst case" scenario model, where the costs, sensitivities, specificities, and complications were all biased against CTA and in favor of CA, the incremental cost-effectiveness of CTA was $690,225 suggesting that CTA was no longer costeffective compared with CA. CTA remained dominant over CA in the two partially biased models.
Discussion
This cost-effectiveness analysis suggests that CTA is preferable to CA to confirm a symptomatic carotid occlusion suspected based on a screening ultrasound or MRA. Despite the superior sensitivity and specificity of CA in the model compared with CTA, the greater cost of CA along with its higher rates of complications shifts the advantage to CTA. In the scenario with all model input variables biased against CTA and in favor of CA, the incremental cost-effectiveness of CTA was no longer in a range considered to be cost-effective. 21 The decision to pursue further diagnostic testing in a patient who is suspected of having an ICA occlusion is a tradeoff between potential complications of the confirmatory test and the need to identify an operable ICA stenosis. Despite CTA's inferior accuracy, its lower complication rate and lower cost compared with CA resulted in a favorable cost-effectiveness ratio in almost all scenarios tested.
For each 100 patients who receive a CTA in place of a CA for evaluation of a carotid occlusion, over $235,000 is saved. Although the difference in total costs between the tests is quite large, the difference in outcomes for the two diagnostic strategies compared in this analysis is small, suggesting that the model results are largely being driven by the relative costs rather than the relative effectiveness. Nonetheless, sensitivity analyses involving both cost and effectiveness variables show that alterations in key probabilities across plausible ranges do not alter the superior cost-effectiveness of CTA in one-and two-way sensitivity analyses, supporting the robustness of the model. Furthermore, omitting CA-related TIA, hematoma, and infection from the model biased the analysis in favor of CA. If these unmodeled variables were to be considered, in addition to patient preferences, the support in favor of CTA would become even stronger. 22 Use of a two-year time horizon, rather than modeling until death, also biased the model in favor of CA. Despite these numerous biases in favor of CA, CTA remained cost-effective compared with CA through all scenarios tested.
Previous cost-effectiveness analyses related to carotid disease have not considered CTA. [23] [24] [25] [26] Furthermore, these studies have dealt with overall strategies for screening for surgical ICA lesions, rather than addressing more focused questions such as the current analysis. Although CTA has limitations, such as differentiating between a moderate and severe stenosis, 27, 28 there have been many series showing that it is an accurate technology for detecting occlusions. 8, 9, 13 When selecting a test for carotid artery evaluation, it is important to select the test based on the specific question being asked.
A recent post-hoc meta-analysis suggested that endarterectomy for the subset of severe stenoses regarded as nearocclusions may not be beneficial when assessing 5-and 8-year outcomes. 29, 30 The validity of these types of subgroup analyses and the statistical methods used are questionable. 31 Nonetheless, the benefit measured at 1 and 3 years post-CEA in those with near-occlusions is better established. 30, 32 Although there is evidence that not all false-positive occlusions detected by CUS or contrast-enhanced MRA can be attributed to nearocclusions, [4] [5] [6] 33 the true proportion is unknown. Sensitivity analysis addressed the impact of altering the benefit of CEA in the severe stenosis group. As the monthly probability of stroke in those who received CEA approached those who did not, CTA remained more cost-effective than CA.
The true accuracy of CTA in detecting carotid artery occlusions is unknown. Studies reporting its accuracy are likely from centers with significant experience with CTA. The accuracy of CTA in less experienced hands may not be so high, which may limit the applicability of our results to centers proficient in CTA performance and interpretation. The sensitivity and specificity of CTA conditional on the ultrasound results may also differ from the primary sensitivity and specificity of CTA. The estimates of CTA sensitivity and specificity reported in the literature may be subject to publication bias; 34 however, the concordance among many studies argues against this being a major factor. As with any cost-utility analysis, the current results are limited by the accuracy of the estimates used in the model.
To mitigate against this, we performed multiple sensitivity analyses across a wide range of values, and included a "worst-case" scenario model.
Conclusion
Given rising health care costs, cost-minimizing diagnostic strategies need to be explored. This analysis suggests that CTA can be used as a less expensive alternative to CA for confirmation of a suspected ICA occlusion, without sacrificing patient outcome.
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